VALN - Valneva reports positive homologous booster data for COVID-19 vaccine VLA2001

Valneva (NASDAQ:VALN) announces positive homologous booster data from the Phase 1/2 study, of its COVID-19 vaccine candidate, VLA2001. Initial results show excellent immune response after third dose of VLA2001 administered 7 to 8 months after the second dose of primary vaccination. Antibody titers increased 42- to 106-fold two weeks after booster dose vs pre-booster levels. Antibody levels after the booster dose were approx. four-fold higher compared to those observed two weeks after primary immunization. In addition, Valneva expects to report further homologous booster data from the Phase 3 Cov-Compare study and is preparing to launch a heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with other vaccines or following natural infection. This study is expected to commence in early 2022. Valneva will also evaluate the sera from the boosted participants for cross-neutralization against Variants of Concern, including Omicron. EU regulator

For further details see:

Valneva reports positive homologous booster data for COVID-19 vaccine, VLA2001